EurekAlert!

A new experimental strategy uses gene editing against tumours with too many oncogenes

In cellular and animal models of neuroblastoma, small cell lung cancer and colon cancer, this strategy reduces tumours, ...

Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
Seeking Alpha

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...
Nasdaq

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...
EurekAlert!

CRISPR enabled precision oncology: from gene editing to tumor microenvironment remodeling

This figure illustrates the evolution of CRISPR technology from 1987 to 2019, presented in a horizontal timeline format and categorized into four generations, each denoted by a distinct color: The ...
BioSpace

FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...
WKYC3

Cleveland Clinic doctors say gene-editing therapy could revolutionize cholesterol treatment

CLEVELAND — Gene editing is the revolution in medical history and a groundbreaking Cleveland Clinic trial is demonstrating how this technology could transform the way millions of Americans manage high ...